Bronchiectasis: A neglected cause of respiratory morbidity and mortality
Authors:
- 1 December 1996
- journal article
- review article
- Published by Wiley in Respirology
- Vol. 1 (4) , 221-225
Abstract
Bronchiectasis is a progressive condition characterized by irreversible destruction and dilation of airways generally associated with chronic bacterial infections. Although in Western countries, the morbidity and mortality from bronchiectasis is considered to have declined markedly in the modern era, the condition continues to cause significant morbidity and mortality in the south‐west Pacific and probably also in South‐East Asia. There is a high prevalence in indigenous populations in the region and factors such as poverty, substandard housing, malnutrition, barriers to medical care and inadequate education are all likely to have a major impact on prevalence and outcome of bronchiectasis. Although bronchiectasis has been viewed as a disease of medium and large airways, there is now increasing evidence of the importance of small airways disease in bronchiectasis and that it may play an integral role in pathogenesis. Chronic inflammation of the bronchial wall by mononuclear cells is common to all types of bronchiectasis. A vicious cycle of bacteria (mediated lung toxicity and bacteria) provoked, host‐mediated inflammatory lung damage has been described. If progressive lung damage with its attendant morbidity and mortality is to be prevented, this vicious cycle needs to be broken. The two distinct therapeutic goals in bronchiectasis are to reduce morbidity and to prevent progression of underlying disease. It may be possible to modulate the host response directly and thus reduce tissue damage, but the precise role of immuno‐modulatory therapy in bronchiectasis is still unclear. The management of this hitherto neglected disease, which reaches almost epidemic proportions in some ethnic groups and is an ongoing source of considerable morbidity and mortality, requires a comprehensive, multidisciplinary approach, which can be modelled on the successful management of chronic asthma in New Zealand.Keywords
This publication has 26 references indexed in Scilit:
- CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types.American Journal of Roentgenology, 1995
- Effect of High-Dose Ibuprofen in Patients with Cystic FibrosisNew England Journal of Medicine, 1995
- Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand: what lessons have been learned?Thorax, 1995
- Prevalence of asthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study.Thorax, 1989
- The immunological component of the cellular inflammatory infiltrate in bronchiectasis.Thorax, 1989
- INDIUM-111-LABELLED GRANULOCYTE ACCUMULATION IN RESPIRATORY TRACT OF PATIENTS WITH BRONCHIECTASISThe Lancet, 1987
- Interpretation of bronchograms and chest radiographs in patients with chronic sputum production.Thorax, 1987
- Ventilatory mechanics in patients with bronchiectasis starting in childhoodThorax, 1974
- Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young childrenJournal of Clinical Pathology, 1971
- A Study of the Pathology and Pathogenesis of BronchiectasisThorax, 1952